Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA ½ÃÀå

Human Recombinant DNA: Global Markets

¸®¼­Ä¡»ç BCC Research
¹ßÇàÀÏ 2022³â 07¿ù »óǰÄÚµå 1105254
ÆäÀÌÁö Á¤º¸ ¿µ¹® 84 Pages ¹è¼Û¾È³»
°¡°Ý
US $ 5,500 £Ü 7,207,000 PDF & Excel (Single User License)
US $ 6,600 £Ü 8,649,000 PDF & Excel (2-5 Users)
US $ 7,920 £Ü 10,379,000 PDF & Excel (Site License)
US $ 9,504 £Ü 12,454,000 PDF & Excel (Enterprise License)


¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA ½ÃÀå Human Recombinant DNA: Global Markets
¹ßÇàÀÏ : 2022³â 07¿ù ÆäÀÌÁö Á¤º¸ : ¿µ¹® 84 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA ½ÃÀå ±Ô¸ð´Â 2022³â±îÁö 3,487¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

½ÃÀåÀº 2022-2027³â ¿¹Ãø±â°£ Áß 7.3%ÀÇ CAGR·Î È®´ëµÇ°í, 2027³â¿¡´Â 4,969¾ï ´Þ·¯¸¦ ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA(Human Recombinant DNA) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Á¦Ç° Á¾·ùº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, COVID-19ÀÇ ¿µÇâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ °³¿ä µîÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¤¸®¿Í ÇÏÀ̶óÀÌÆ®

Á¦3Àå °³¿ä

Á¦4Àå COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ

Á¦6Àå ½ÃÀå ³»¿ª, Á¦Ç° Á¾·ùº°

  • Àΰ£ ´Ü¹éÁú ġȯ
  • Àΰ£ ÁúȯÀ» À§ÇÑ Ä¡·áÁ¦
  • ¹é½Å
  • ¹é½Å Á¾·ù

Á¦7Àå ½ÃÀå ³»¿ª, ÃÖÁ¾»ç¿ëÀÚº°

  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¾÷°è, Á¦¾à »ê¾÷
  • Çмú¿¬±¸±â°ü

Á¦8Àå ½ÃÀå ³»¿ª, Áö¿ªº°

  • Áö¿ªº° ¼¼°è ½ÃÀå
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª

Á¦9Àå °æÀï »óȲ

Á¦10Àå ±â¾÷ °³¿ä

  • ABBVIE INC.
  • ALEXION PHARMACEUTICALS
  • AMGEN INC.
  • ELI LILLY
  • MERCK & CO. INC.
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICAL CO LTD.
KSM 22.08.05

List of Tables

  • Summary Table : Global Market for Human Recombinant DNA, by Region, Through 2027
  • Table 1 : Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
  • Table 2 : Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
  • Table 3 : Global Human Recombinant DNA Market, by Product Type, Through 2027
  • Table 4 : Global Market for Human Protein Replacements, by Region, Through 2027
  • Table 5 : Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
  • Table 6 : Vaccine Types
  • Table 7 : Global Market for Vaccines, by Region, Through 2027
  • Table 8 : Global Market for Human Recombinant DNA, by End User, Through 2027
  • Table 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
  • Table 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
  • Table 11 : Global Market for Human Recombinant DNA, by Region, Through 2027
  • Table 12 : North American Market for Human Recombinant DNA, by Product Type Through 2027
  • Table 13 : North American Market for Human Recombinant DNA, by End User, Through 2027
  • Table 14 : North American Market for Human Recombinant DNA, by Country, Through 2027
  • Table 15 : European Market for Human Recombinant DNA, by Product Type, Through 2027
  • Table 16 : European Human Recombinant DNA Market, by End User, Through 2027
  • Table 17 : European Market for Human Recombinant DNA, by Country, Through 2027
  • Table 18 : Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
  • Table 19 : Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
  • Table 20 : Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
  • Table 21 : Japan: Total Number of New Cancer Cases in Both Genders, 2020
  • Table 22 : RoW Market for Human Recombinant DNA, by Product Type, Through 2027
  • Table 23 : RoW Market for Human Recombinant DNA, by End User, Through 2027
  • Table 24 : Leading Market Players in the Human Recombinant DNA Market Ecosystem
  • Table 25 : AbbVie Inc.: Business Segments
  • Table 26 : AbbVie Inc.: Financial Performance, Through 2020
  • Table 27 : Amgen: Financial Performance, Through 2020
  • Table 28 : Eli Lilly: Business Segments
  • Table 29 : Eli Lilly: Financial Performance, 2018-2020
  • Table 30 : Sanofi: Business Segments
  • Table 31 : Sanofi: Financial Performance, 2018-2020

List of Figures

  • Summary Figure A : Global Market for Human Recombinant DNA, by Region, 2020-2027
  • Summary Figure B : Global Market Shares of Human Recombinant DNA, by Region, 2021
  • Figure 1 : Global Market Shares of Human Recombinant DNA, by Product Type, 2021
  • Figure 2 : Global Market for Human Recombinant DNA, by Product Type, 2020-2027
  • Figure 3 : Global Market for Human Protein Replacements, 2020-2027
  • Figure 4 : Global Market for Therapeutic Agents for Human Diseases, 2020-2027
  • Figure 5 : Evolution of Vaccine Technologies
  • Figure 6 : Global Market for Vaccines, 2020-2027
  • Figure 7 : Global Market Shares of Human Recombinant DNA, by End User, 2021
  • Figure 8 : Global Market for Human Recombinant DNA, by End User, 2020-2027
  • Figure 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020-2027
  • Figure 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020-2027
  • Figure 11 : Global Market Shares of Human Recombinant DNA, by Region, 2021
  • Figure 12 : North American Market Shares of Human Recombinant DNA, by Product Type, 2021
  • Figure 13 : North American Market Shares of Human Recombinant DNA, by End User, 2021
  • Figure 14 : North American Market Shares of Human Recombinant DNA, by Country, 2021
  • Figure 15 : U.S. Market for Human Recombinant DNA, 2020-2027
  • Figure 16 : Canadian Market for Human Recombinant DNA, 2020-2027
  • Figure 17 : European Market Shares of Human Recombinant DNA, by Product Type, 2021
  • Figure 18 : European Human Recombinant DNA Market, Market Shares, by End User, 2021
  • Figure 19 : European Market Shares of Human Recombinant DNA, by Country, 2021
  • Figure 20 : Geriatric Population in Germany, 2000-2030
  • Figure 21 : German Market for Human Recombinant DNA, 2020-2027
  • Figure 22 : U.K. Market for Human Recombinant DNA, 2020-2027
  • Figure 23 : French Market for Human Recombinant DNA, 2020-2027
  • Figure 24 : Italian Market for Human Recombinant DNA, 2020-2027
  • Figure 25 : Spanish Market for Human Recombinant DNA, 2020-2027
  • Figure 26 : Rest of Europe Market for Human Recombinant DNA, 2020-2027
  • Figure 27 : Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
  • Figure 28 : Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
  • Figure 29 : Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
  • Figure 30 : New Cancer Cases in China, 2020
  • Figure 31 : Distribution of New Cancer Cases in China, 2020
  • Figure 32 : Chinese Market for Human Recombinant DNA, 2020-2027
  • Figure 33 : Japanese Market for Human Recombinant DNA, 2020-2027
  • Figure 34 : Indian Market for Human Recombinant DNA, 2020-2027
  • Figure 35 : Rest of Asia-Pacific Market for Human Recombinant DNA, 2020-2027
  • Figure 36 : New Cancer Cases in Africa, 2020
  • Figure 37 : RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
  • Figure 38 : RoW Market Shares of Human Recombinant DNA, by End User, 2021
  • Figure 39 : AbbVie Inc.: Net Revenue, by Business Segment, 2020
  • Figure 40 : AbbVie Inc.: Net Revenue, by Region, 2020
  • Figure 41 : Amgen: Total Sales, by Product, 2020
  • Figure 42 : Amgen: Total Revenue, by Region, 2020
  • Figure 43 : Eli Lilly: Total Sales, by Product Segment, 2020
  • Figure 44 : Eli Lilly: Total Revenue, by Region, 2020
  • Figure 45 : Sanofi: Net Sales, by Business Segment, 2020
  • Figure 46 : Sanofi: Net Sales, by Region, 2020

Highlights:

The global human recombinant DNA market should reach $348.7 billion by 2022 and more than $496.9 billion by 2027, with a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2022-2027.

North American human recombinant DNA market should reach $150.8 billion by 2022 and more than $191.7 billion by 2027, with a CAGR of 4.9% during the forecast period of 2022-2027.

Asia-Pacific human recombinant DNA market should reach $86 billion by 2022 and more than $136.2 billion by 2027, with a CAGR of 9.6% during the forecast period of 2022-2027.

Report Scope:

This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.

Report Includes:

  • 24 data tables and 8 additional tables
  • An overview of the global market for human recombinant DNA
  • Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
  • Highlights of the market potential for human recombinant DNA, based on product, application, and region
  • Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
  • Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi

Table of Contents

Chapter 1 Introduction

  • Introduction
  • Study Goals and Objectives
  • Reasons for Doing the Study
  • Intended Audience
  • Scope and Format
  • Methodology
  • Market Estimates
  • Information Sources
  • Geographical Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Homologous Recombination (HR)
  • Targets for Cancer Therapy

Chapter 4 Impact of COVID-19 Pandemic

Chapter 5 Market Dynamics

  • Market Drivers
  • Increasing Incidences of Chronic Diseases
  • Growing Aging Population
  • Advancements in Manufacturing Technologies
  • Market Restraints
  • Price Controls
  • Entry of Biosimilars
  • Opportunities
  • Untapped Potential in Emerging Markets

Chapter 6 Market Breakdown by Product Type

  • Human Protein Replacements
  • Market Size and Forecast
  • Therapeutic Agents for Human Diseases
  • Market Size and Forecast
  • Vaccines
  • Types of Vaccines
  • Market Size and Forecast

Chapter 7 Market Breakdown by End User

  • Biotechnology and Pharmaceutical Industry
  • Market Size and Forecast
  • Research Laboratories and Academic Institutes
  • Market Size and Forecast

Chapter 8 Market Breakdown by Region

  • Global Market by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 9 Competitive Landscape

  • Overview

Chapter 10 Company Profiles

  • ABBVIE INC.
  • ALEXION PHARMACEUTICALS
  • AMGEN INC.
  • ELI LILLY
  • MERCK & CO. INC.
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICAL CO LTD.
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q